論文（英文）

Usui T, Yoshida Y, Nishi H, Yanagimoto S, Matsuyama Y, Nangaku M. Diagnostic accuracy of urine dipstick for proteinuria category in Japanese workers. Clin Exp Nephrol. 2020; 24(2): 151-156.
Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2020; 50(1): 15-46.
Yoshida M, Miura Y, Okada S, Yamada M, Kagaya H, Saitoh E, Kamakura Y, Okawa Y, Matsuyama Y, Sanada H. Effectiveness of swallowing care on safe oral intake using ultrasound-based observation of residues in the epiglottis valley: A pragmatic, quasi-experimental study. Healthcare 2020; 8(1).
Taniguchi Y, Kitamura A, Kaito S, Yokoyama Y, Yokota I, Shinozaki T, Seino S, Murayama H, Matsuyama Y, Ikeuchi T, Fujiwara Y, Shinkai S. Albumin and hemoglobin trajectories and incident disabling dementia in community-dwelling older Japanese. Dement Geriatr Cogn Disord. 2019; 47: 233-242.
Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019; 49(10): 1109-1113.
Taniguchi Y, Kitamura A, Ishizaki T, Fujiwara Y, Shinozaki T, Seino S, Mitsutake S, Suzuki H, Yokoyama Y, Abe T, Ikeuchi T, Yokota I, Matsuyama Y, Shinkai S. Association of trajectories of cognitive function with cause-specific mortality and medical and long-term care costs. Geriatr Gerontol Int. 2019; 19(12): 1236-1242.
Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019; 8(5): 403-411.
Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg. 2019; 270(1): 121-130.
Takao T, Matsuyama Y, Suka M, Yanagisawa H, Kasuga M. Analysis of the duration and extent of the legacy effect in patients with type 2 diabetes: A real-world longitudinal study. J Diabetes Complications. 2019; 33(8): 516-522.
Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: Report of a Japanese nationwide survey. Annals of Surgery 2019; 269(4): 692-699.
Taniguchi Y, Kitamura A, Nofuji Y, Ishizaki T, Seino S, Yokoyama Y, Shinozaki T, Murayama H, Mitsutake S, Amano H, Nishi M, Matsuyama Y, Fujiwara Y, Shinkai S. Association of trajectories of higher-level functional capacity with mortality and medical and long-term care costs among community-dwelling older Japanese. J Gerontol A Biol Sci Med Sci. 2019; 74(2): 211-218.
Hagiwara Y, Shinozaki T, Matsuyama Y. G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome. Biometrics. 2020;76:799–810.
Yoshida T, Uchino S, Sasabuchi Y, Hagiwara Y, the AFTER-ICU study group. Prognostic impact of sustained new-onset atrial fibrillation in critically ill patients. Intensive Care Med. 2020;46:27–35.
Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey. Mol Genet Metab Rep. 2019;20:100496.
Trotta L, Kabeya Y, Buyse M, Doffagne E, Venet D, Desmet L, Burzykowski T, Tsuburaya A, Yoshida K, Miyashita Y, Morita S, Sakamoto J, Praveen P, Oba K. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. Clin Trials. 2019 Jul 23:1740774519862564.
Tominaga T, Akiyoshi T, Yamamoto N, Oba K, Nagasaki T, Yamaguchi T, Konishi T, Fukunaga Y, Ueno M. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Surgery. 2019 Jul 22.
Shinagawa T, Hata K, Ikeuchi H, Fukushima K, Futami K, Sugita A, Uchino M, Watanabe K, Higashi D, Kimura H, Araki T, Mizushima T, Itabashi M, Ueda T, Koganei K, Oba K, Ishihara S, Suzuki Y. Clin Gastroenterol Hepatol. 2019 Jul 20.
Nagata H, Ishihara S, Oba K, Tanaka T, Hata K, Kawai K, Nozawa H. Development and Validation of a Prediction Model for Organ-Specific Recurrences After Curative Resection of Colon Cancer. Dis Colon Rectum. 2019 Jul 12.
Sugiyama T, Oba K, Kobayashi Y. Risk-Stratified Incidence of Renal Replacement Therapy Initiation: A Longitudinal Analysis Using Medical Claims and Health Checkup Data. Tohoku J Exp Med. 2019 Jun;248(2):125-135.
Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist. 2019 Jun 19. pii: theoncologist.2019-0133. doi: 10.1634/theoncologist.2019-0133.
Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019 Jun 13. doi: 10.1002/bjs.11179.
Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of second-generation drug-eluting stent -integrated analysis of quantitative coronary angiography from four post-marketing surveillances of cobalt-chromium everolimus-eluting stent in Japan-. Int Heart J. 2019, in press.
Ota K, Fukui K, Oba K, Shimoda A, Oka M, Ota K, Sakaue M, Takasu A. The role of ultrasound imaging in adult patients with testicular torsion: a systematic review and meta-analysis. J Med Ultrason (2001). 2019 Mar 7. doi: 10.1007/s10396-019-00937-3.
Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. Int J Clin Oncol. Int J Clin Oncol. 2019 Feb 18. doi: 10.1007/s10147-019-01414-0.
Kobayashi S, Kishi R, Saijo Y, Ito Y, Oba K, Araki A, Miyashita C, Itoh S, Minatoya M, Yamazaki K, Ait Bamai Y, Sato T, Yamazaki S, Nakayama SF, Isobe T, Nitta H; Japan Environment and Children's Study Group. Association of blood mercury levels during pregnancy with infant birth size by blood selenium levels in the Japan Environment and Children's Study: A prospective birth cohort. Environ Int. 2019 Apr;125:418-429.
Maeda H, Nagata N, Nagasaka T, Oba K, Mishima H, Kato T, Yoshida K, Muro K, Sakamoto J. A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. Oncol Lett. 2019 Feb;17(2):1980-1985.
Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. J Cancer. 2018 Oct 18;9(22):4092-4098.

TOP